| A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age (NCT07406347) | GlaxoSmithKline | 2027-01-25 |
| A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment (NCT07609706) | GlaxoSmithKline | 2026-10-23 |
| A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care (NCT07742527) | GlaxoSmithKline | 2026-10-16 |
| Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03] (NCT07694427) | GlaxoSmithKline | 2026-10-09 |
| A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) (NCT07684612) | GlaxoSmithKline | 2026-09-22 |
| A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer (NCT07740720) | GlaxoSmithKline | 2026-09-17 |
| A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) (NCT07645248) | GlaxoSmithKline | 2026-09-15 |
| A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) (NCT07602855) | GlaxoSmithKline | 2026-09-08 |
| A Study to Investigate GSK5733584 as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02) (NCT07684599) | GlaxoSmithKline | 2026-09-03 |
| A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib (NCT07689201) | GlaxoSmithKline | 2026-08-31 |
| A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events (NCT07712380) | GlaxoSmithKline | 2026-08-31 |
| A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer (NCT07652515) | GlaxoSmithKline | 2026-08-17 |
| A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age (NCT07742644) | GlaxoSmithKline | 2026-08-11 |
| A Study to Investigate the Safety and Tolerability of Multiple Study Interventions in Participants With Moderate to Severe Ulcerative Colitis (NCT07747467) | GlaxoSmithKline | 2026-08-10 |
| A Sub Study to Investigate the Safety and Tolerability of Aletekitug in Participants With Moderate To Severe Ulcerative Colitis (NCT07747480) | GlaxoSmithKline | 2026-08-10 |
| A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome (NCT07569081) | GlaxoSmithKline | 2026-08-05 |
| Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma (NCT07614360) | GlaxoSmithKline | 2026-08-03 |
| A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria (NCT07545681) | GlaxoSmithKline | 2026-07-28 |
| A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) (NCT07701993) | GlaxoSmithKline | 2026-07-22 |
| A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) (NCT07704892) | GlaxoSmithKline | 2026-07-22 |
| Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (NCT07701967) | GlaxoSmithKline | 2026-07-20 |
| A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283 (NCT07712393) | GlaxoSmithKline | 2026-07-17 |
| A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) (NCT07585266) | GlaxoSmithKline | 2026-07-10 |
| A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women (NCT07645235) | GlaxoSmithKline | 2026-07-09 |
| A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes (NCT07684586) | GlaxoSmithKline | 2026-07-02 |
| A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years (NCT07596173) | GlaxoSmithKline | 2026-06-29 |
| A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women (NCT07596199) | GlaxoSmithKline | 2026-06-29 |
| Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years (NCT07670377) | GlaxoSmithKline | 2026-06-26 |
| A Study of Depemokimab in Participants of 6 to 11 Years of Age (NCT07671001) | GlaxoSmithKline | 2026-06-26 |
| A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults (NCT07663032) | GlaxoSmithKline | 2026-06-24 |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis (NCT07224672) | GlaxoSmithKline | 2026-06-24 |
| A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) (NCT07602777) | GlaxoSmithKline | 2026-06-22 |
| A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (NCT07286266) | GlaxoSmithKline | 2026-06-18 |
| A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL (NCT07607925) | GlaxoSmithKline | 2026-06-12 |
| First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults (NCT07646353) | GlaxoSmithKline | 2026-06-12 |
| A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults (NCT07628049) | GlaxoSmithKline | 2026-06-05 |
| A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) (NCT07286331) | GlaxoSmithKline | 2026-06-04 |
| A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive (NCT07600450) | GlaxoSmithKline | 2026-05-15 |
| A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose (NCT07406334) | GlaxoSmithKline | 2026-05-15 |
| A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics (NCT07371429) | GlaxoSmithKline | 2026-04-29 |
| A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) (NCT07227311) | GlaxoSmithKline | 2026-04-15 |
| A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M) (NCT07519395) | GlaxoSmithKline | 2026-04-08 |
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (NCT07286370) | GlaxoSmithKline | 2026-04-01 |
| A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland (NCT07502560) | GlaxoSmithKline | 2026-03-31 |
| First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors (NCT07438782) | GlaxoSmithKline | 2026-03-23 |
| A Study of Efimosfermin Alfa in Adults With Hepatic Impairment (NCT07358546) | GlaxoSmithKline | 2026-03-13 |
| A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma (NCT07456033) | GlaxoSmithKline | 2026-03-13 |
| Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years (NCT07428759) | GlaxoSmithKline | 2026-03-10 |
| A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (NCT07464314) | GlaxoSmithKline | 2026-03-09 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry (NCT07335198) | GlaxoSmithKline | 2026-03-05 |
| First-Time-in-Human Study of GSK5471713 in Adults With mCRPC (NCT07332455) | GlaxoSmithKline | 2026-02-10 |
| A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) (NCT07371468) | GlaxoSmithKline | 2026-02-10 |
| Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (NCT07320716) | GlaxoSmithKline | 2026-01-02 |
| Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) (NCT06405230) | GlaxoSmithKline | 2025-12-30 |
| A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH (NCT07221188) | GlaxoSmithKline | 2025-12-12 |
| A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (NCT07277270) | GlaxoSmithKline | 2025-12-03 |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy (NCT07218926) | GlaxoSmithKline | 2025-12-03 |
| A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) (NCT07108270) | GlaxoSmithKline | 2025-11-27 |
| A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough - China Extension (NCT07650084) | GlaxoSmithKline | 2025-11-21 |
| A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis (NCT07201051) | GlaxoSmithKline | 2025-10-30 |
| A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease (NCT07220109) | GlaxoSmithKline | 2025-10-29 |
| A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH (NCT07221227) | GlaxoSmithKline | 2025-10-24 |
| A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors (NCT07213609) | GlaxoSmithKline | 2025-10-20 |
| eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation (NCT07177339) | GlaxoSmithKline | 2025-10-20 |
| A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above (NCT07204964) | GlaxoSmithKline | 2025-10-07 |
| A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease (NCT07168356) | GlaxoSmithKline | 2025-09-26 |
| Open-label Extension Study in Participants With Early Alzheimer's Disease (NCT07105709) | GlaxoSmithKline | 2025-08-14 |
| A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age (NCT07105722) | GlaxoSmithKline | 2025-08-12 |
| A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) (NCT07099898) | GlaxoSmithKline | 2025-08-11 |
| A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant (NCT07092865) | GlaxoSmithKline | 2025-08-06 |
| A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months (NCT07036159) | GlaxoSmithKline | 2025-08-06 |
| A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults (NCT07085702) | GlaxoSmithKline | 2025-07-29 |
| Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) (NCT06961214) | GlaxoSmithKline | 2025-06-23 |
| Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) (NCT06959095) | GlaxoSmithKline | 2025-06-20 |
| A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer (NCT06990880) | GlaxoSmithKline | 2025-06-12 |
| A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) (NCT06885034) | GlaxoSmithKline | 2025-06-11 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry (NCT06979518) | GlaxoSmithKline | 2025-05-20 |
| A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (NCT06806137) | GlaxoSmithKline | 2025-05-15 |
| A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer (NCT06887933) | GlaxoSmithKline | 2025-04-22 |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (NCT06855160) | GlaxoSmithKline | 2025-04-17 |
| A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH (NCT06920043) | GlaxoSmithKline | 2025-04-09 |
| A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma (NCT06702462) | GlaxoSmithKline | 2025-03-11 |
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer (NCT06521567) | GlaxoSmithKline | 2025-03-06 |
| A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) (NCT06796907) | GlaxoSmithKline | 2025-03-04 |
| Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis (NCT06517875) | GlaxoSmithKline | 2025-02-28 |
| A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (NCT06567782) | GlaxoSmithKline | 2025-02-18 |
| A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma (NCT06748053) | GlaxoSmithKline | 2025-02-10 |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age (NCT06740630) | GlaxoSmithKline | 2025-01-10 |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (NCT06679101) | GlaxoSmithKline | 2024-12-16 |
| A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE) (NCT06716606) | GlaxoSmithKline | 2024-12-12 |
| A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease (NCT06734234) | GlaxoSmithKline | 2024-12-11 |
| A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age (NCT06693895) | GlaxoSmithKline | 2024-11-26 |
| A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age (NCT06702449) | GlaxoSmithKline | 2024-11-19 |
| A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants (NCT06681181) | GlaxoSmithKline | 2024-11-18 |
| An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older (NCT06666491) | GlaxoSmithKline | 2024-11-13 |
| A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (NCT06663436) | GlaxoSmithKline | 2024-11-13 |
| A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) (NCT06537414) | GlaxoSmithKline | 2024-11-11 |
| A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults (NCT06680375) | GlaxoSmithKline | 2024-11-11 |
| A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China (NCT06640049) | GlaxoSmithKline | 2024-10-17 |
| A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib (NCT06625489) | GlaxoSmithKline | 2024-10-07 |